OR WAIT null SECS
Kindeva’s acquisition of iPharma will increase the company’s inhalation formulation outsourcing capabilities.
Kindeva Drug Delivery, a contract manufacturing and development organization (CDMO), completed its acquisition of iPharma Labs, a CDMO focused on inhaled medicines, on June 16, 2022. The entire team at iPharma has joined Kindeva and will continue to operate at their existing location.
iPharma specializes in inhalation formulation and the development of liquid, dry powder, and propellant-based therapies. According to a company press release, iPharma has worked with dry powder inhalation, soft mist inhalers, and nebulizers for both small and large molecules, including biologics, in the early stages of drug development.
“We’re pleased to offer this combination to our customers and their patients: a complete portfolio of respiratory delivery expertise all in one global team,” said Arron Mann, CEO, Kindeva, in the press release. “[The team at iPharma] will help Kindeva accelerate our one-stop CDMO approach: addressing our customers’ desire for a single partner to support feasibility through commercialization without lengthy and risky hand-offs.”
“Joining Kindeva strengthens our ability to craft the best product development strategy for delivery to the patient to and through the lungs,” said Keith Ung, CEO and co-founder, iPharma, in the press release. “Our customers are already excited to benefit from a more complete product development and manufacturing offering. I look forward to leading efforts at Kindeva to expand our clinical and commercial support for dry powder and nebulized respiratory therapies.”
Source: Kindeva Drug Delivery